Renal cell carcinoma (RCC) is among the most lethal urological malignancies once
metastatic. The introduction of immune checkpoint inhibitors has revolutionized the …

Renal cell carcinoma (RCC) is a kidney cancer with an onset mainly during the sixth or
seventh decade of the patient's life. Patients with advanced, metastasized RCC have a poor …

Modeling renal cell carcinoma is critical to investigating tumor biology and therapeutic
mechanisms. Multiple systems have been developed to represent critical components of the …

Immune checkpoint inhibitors have significantly transformed the treatment paradigm for
metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving …

The objective of the present work was to establish a large panel of preclinical models of
human renal cell carcinoma (RCC) directly from patients, faithfully reproducing the biological …

Immunotherapy has revolutionized the treatment landscape for many cancer types. The
treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from …

Introduction: Renal cell carcinoma is no longer considered a monolithic disease, but a group
of different entities exhibiting unique molecular alterations requiring a tailored systemic …

Over the past decade, the treatment landscape for patients with metastatic renal cell
carcinoma (RCC) has evolved dramatically. The therapeutic options available have …

Globally, clear-cell renal cell carcinoma (ccRCC) represents the most prevalent type of
kidney cancer. Surgery plays a key role in the treatment of this cancer, although one third of …

Simple Summary Over the last decade there has been a significant increase in the number
of therapies that activate the host's immune system to target and eliminate renal cell …